CBER Draft Review Template To Debut In April 2005
This article was originally published in The Pink Sheet Daily
The review template should be released for public comment in six months, CBER’s Leonard Wilson says. The guidelines are based on the drug center’s review template.
You may also be interested in...
Center for Biologics Evaluation & Research annual report says review management senior leadership is being moved to “co-locate” with product reviewers to facilitate implementation of measures aimed at enhancing reviews.
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.